Drug Shortage Legislation Gains Support As Coronavirus Threatens US Supplies
Coronavirus hysteria sweeps up languishing drug shortage legislation; prospects for new reporting and risk management planning requirements improve.
You may also be interested in...
Joe Biden’s presidential campaign now has a plan to address supply chains and encourage US-based manufacturing of prescription drugs. That affirms the unlikely national prominence of the issue – and reduces the chances of meaningful legislation this year.
Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.
House coronavirus legislation would boost domestic manufacturing capacity while further scrutinizing global supply chain.